

## ORIGINAL ARTICLE

# Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what's it worth?

Elliot Tapper<sup>1</sup>, Bobby Kalb<sup>2</sup>, Diego R. Martin<sup>2</sup>, David Kooby<sup>3</sup>, N. Volkan Adsay<sup>4</sup> & Juan M. Sarmiento<sup>3</sup>

<sup>1</sup>Department of Medicine, Beth Israel Deaconess Medical Centre, Boston, MA, USA, and Departments of <sup>2</sup>Radiology, <sup>3</sup>Surgery and <sup>4</sup>Pathology, Emory University, Atlanta, GA, USA

## Abstract

**Background:** Preoperative imaging is often inadequate in excluding unresectable pancreatic cancer. Accordingly, many groups employ staging laparoscopy (SL), although none have evaluated SL after preoperative magnetic resonance imaging (MRI). We performed a retrospective, indirect cost-effectiveness analysis of SL after MRI for pancreatic head lesions.

**Methods:** All MRI scans administered for proximal pancreatic cancer between 2004 and 2008 were reviewed and the clinical course of each patient determined. We queried our billing database to render average total costs for all inpatients with proximal pancreatic cancer who underwent pancreaticoduodenectomy, palliative bypass or an endoscopic stenting procedure. We then performed an indirect evaluation of the cost of routine SL.

**Results:** The average costs of hospitalization for patients undergoing pancreaticoduodenectomy, open palliative bypass and endoscopic palliation were: US\$26 122.43, US\$21 957.18 and US\$11 304.00, respectively. The calculated cost of SL without laparotomy was US\$2966.25 or US\$1538.61 prior to laparotomy. The calculated cost of treating unresectable disease by outpatient laparoscopy followed by endoscopy was US\$5943.17. Routine SL would increase our costs by US\$76 967.46 (3.6%).

**Conclusions:** Staging laparoscopy becomes cost-effective by diverting unresectable patients from operative to endoscopic palliation. Given the paucity of missed metastases on MRI, the yield of SL is marginal and its cost-effectiveness is poor. Future studies should address the utility of SL by both examining this issue prospectively and investigating the cost-effectiveness of endoscopic vs. surgical palliation in a manner that takes account of survival and quality of life data.

## Keywords

pancreatic adenocarcinoma, pancreaticoduodenectomy, staging laparoscopy, surgical palliation for pancreatic neoplasia, hepaticojejunostomy, gastrojejunostomy, cost-effectiveness

Received 8 April 2011; accepted 8 June 2011

## Correspondence

Juan M. Sarmiento, Department of Surgery, Emory University Hospital, 1364 Clifton Road, NE Suite H-124-C, Atlanta, GA 30322, USA. Tel: +1 404 727 1540. Fax: +1 404 712 2739. E-mail: jsarmie@emory.edu

## Introduction

Pancreatic cancer presents late in its natural history and thus those with resectable disease account for only 15–20% of all pancreatic cancer patients.<sup>1–3</sup> Some patients, however, present in time to undergo pancreaticoduodenectomy – the Whipple procedure – which offers the only potential cure for malignant lesions in or

This paper is based on a poster presentation given at the Society for Surgery of the Alimentary Tract and Pancreas Club Meeting, 1 May 2010, New Orleans, Louisiana.

around the head of the pancreas. To determine resectability, surgeons often choose computed tomography (CT).<sup>4,5</sup> Unfortunately, CT is often inadequate in determining unresectability. Although the accuracy of CT has improved over time, as many as 10–48% of those deemed resectable on CT are taken to laparotomy for ultimately unresectable disease.<sup>2,5–10</sup> Some studies have explored the role of magnetic resonance imaging (MRI) in this setting, but these are few and increasingly dated.<sup>4,11–14</sup> Our group recently reported that, in our experience, MRI offers sensitivity of 100% for resectable disease and specificity of 73.2–78.9%.<sup>15</sup> Although a

number of patients were taken for laparotomy with what turned out to be unresectable disease, crucially only six (6.4%) had metastases, four (4.3%) of which were in the liver. An option advocated by many groups is to employ staging laparoscopy (SL). As our group does not regularly use SL in the management of pancreatic cancer, we performed a cost analysis of this procedure in the setting of our MRI-driven practice.

The strength of the case for SL is dependent on the yield of laparoscopy, which is inversely proportional to the quality of preoperative imaging and further constrained by the field of laparoscopic visualization. Many groups report high yields for SL, which finds metastases missed on CT in as many as 37% of cases.<sup>2,16,17</sup> The prevalence of CT-occult metastases has prompted several groups to support SL in a manner that presupposes its ability to detect tumours that are unseen on imaging.<sup>18–20</sup> This may give SL too much credit for four reasons. Firstly, even presuming a lack of human error, the camera may not capture deep hepatic and low omental metastases. Indeed, 7–35% of patients receiving SL have metastases that are later discovered at laparotomy.<sup>6,9,17,21,22</sup> Secondly, the potential yield of SL declines as the accuracy of preoperative imaging improves.<sup>23</sup> Thirdly, metastases are not the only reason to abort the Whipple procedure; SL is fundamentally limited in describing the extent of locoregional disease and its resectability in terms of vascular invasion. Finally, the unspoken premise of SL is that the patient with disease that is not amenable to pancreaticoduodenectomy *should* be spared a laparotomy. This is a value judgement based on physician and patient preference for operative vs. endoscopic palliation that is related, in part, to the surgical candidacy of the patient.

Justly, several groups have investigated the cost-effectiveness of SL. Despite their varied conclusions, on balance the data seem to indicate a small but positive cost : benefit ratio for SL after preoperative CT.<sup>9,10,21,24–26</sup> Herein, we present a study of the cost-effectiveness of SL in an MRI-driven practice.

## Materials and methods

### Assessing the MRI-driven practice

As described in a previous paper,<sup>15</sup> we undertook a retrospective review of all MRI scans administered for suspected pancreatic cancer at Emory University Hospital in the 4-year period between December 2004 and December 2008. Institutional review board approval was ascertained and a Microsoft Excel database was created to house data for all patients who were evaluated and treated for this prospective radiographic diagnosis. Patient, tumour and radiographic features were reviewed. Patient factors included age, sex and days between MRI and operation. Tumour factors included histopathological diagnosis and nodal status. Radiographic features included comments on the presence of metastases and the relationship of the tumour with the surrounding vasculature. In concert with the surgeons, our radiologists are able to give one of three diagnoses of unresectable, resectable or borderline disease. 'Unresectable' disease is defined as the presence of metastases or significant vascular

invasion or encasement that is clearly not amenable to reconstructive surgery. In such cases, the diagnosis of pancreatic cancer is made by open biopsy during a palliative procedure, by CT-guided biopsy or by endoscopic brushings. These patients then undergo a palliative procedure, usually of endoscopic biliary with or without duodenal stenting. 'Resectable' disease denotes the absence of metastases and vascular involvement, and 'borderline' disease denotes tumours that significantly abut or compress otherwise patent vasculature (superior mesenteric vein, portal vein, hepatic artery, superior mesenteric artery). All radiological and pathological examinations were carried out at our institution. Histopathological diagnosis represents the reference standard.

### Cost analysis

Using the experiences derived from the methods described above, we investigated the cost-effectiveness of incorporating SL for those patients deemed by radiography to have resectable or borderline resectable disease. Total costs were acquired from our financial department; these were accurate at April 2009. Total costs were abstracted directly from accounting ledgers and included the fixed costs of operations and variable direct costs (labour, supply, overheads), as well as standard indirect costs. We did not include any dollar values for which the sum was negotiable, such as professional fees. Accordingly, these costs are not charges; they represent the total cost incurred by the hospital for a given operation.

Average total costs for all patients treated for adenocarcinoma of the head of the pancreas in a 1-year period (April 2008 to April 2009) were assessed. This group of patients was further divided according to ICD-9 codes into those who received Whipple procedures (code 52.7), operative palliative bypasses (codes 51.37 and 44.39) and endoscopic palliative bypasses (codes 51.87 and 52.93), respectively. These values were derived from data on the hospitalizations of all patients who received care for pancreatic cancer delivered by all pancreatic surgeons at our centre. This includes patients in whom CT alone represented the only preoperative imaging. The costs of preoperative imaging were not included in the analysis as these would cancel out across the comparisons.

The costs of inpatient palliative endoscopy were those of the average patient hospitalized with a diagnosis of pancreatic adenocarcinoma and discovered to have metastatic disease on preoperative imaging. Many patients undergo endoscopy as outpatients; when these patients were considered in our study, we included only those costs generated in the endoscopy laboratory.

The costs of SL were identified using ICD-9 codes 54.2–54.29. They were further simplified as the itemized average costs of the materials, space and ancillary staff manpower. We assumed that the procedure required 30 min of operating room (OR) time and 30 min of anaesthetist time. We also assumed that the procedure would be converted to a laparotomy if the SL found no metastases. Accordingly, the costs of those materials routinely used in laparotomy and therefore already accounted for in the OR costs of the Whipple or palliative bypass groups were discounted (e.g. bispec-

tral index [BIS] monitoring, drapes, spontaneous compression devices, suction, Foley catheter, dermabond, post-anaesthesia care). If the SL was positive, the average costs of surgical pathology for patients receiving SL were included. The costs of perioperative laboratory testing and pharmacology were included explicitly in our consideration of outpatient laparoscopy, but were already included in the total cost of these services for hospitalized patients. This model presumes routine utilization (all patients); furthermore, it presumes no false negatives (no missed metastases on laparoscopy) and no intraoperative complications of laparoscopy (no bleeding or open conversions for unresectable disease).

The cost-effectiveness of laparoscopy was determined in the following fashion. First, the cost of the MRI-driven practice was assessed. Second, the cost of treating resectable disease by the Whipple procedure with laparoscopy was subtracted from that total to yield the cost of treating unresectable disease. Third, as the laparoscopy intervention both added cost and reduced the number of patients receiving operative bypasses by diverting them towards endoscopic palliation, a formula was constructed to determine the number of metastases required for laparoscopy to be cost-effective:

$$\text{(cost of care for patients with unresectable disease in the MRI-driven practice)} = (\text{total number of patients with unresectable disease caused by metastases and vascular invasion} - x) \times (\text{cost of hospitalization with operative bypass and laparoscopy for unresectable disease}) + x \times (\text{cost of hospitalization with endoscopic palliation and laparoscopy for unresectable disease}),$$

where  $x$  is the number of metastases found at laparoscopy. This calculation was repeated with the cost of outpatient management in place of that of inpatient endoscopic palliation.

## Results

### The outcomes of an MRI-driven practice

We identified 124 patients who received MRI for preoperative imaging of suspected pancreatic adenocarcinoma during the 4-year period under review. Thirty patients had unresectable disease and 94 patients were offered the Whipple procedure. Of the latter 94 patients, 41 had borderline resectable disease. Eight of the 94 patients declined an operation and 86 proceeded to the OR, where 65 received completed Whipple procedures, 20 received bypass operations and one received an exploratory laparotomy for benign disease (biopsy-proven pancreatitis). Whipple procedures were aborted in 11 of the 50 patients (22%) with resectable disease and 10 of the 36 (28%) patients with borderline resectable disease who proceeded to the OR (no significant difference). Of the 21 patients in whom Whipple procedures were aborted, 13 were found to have vascular invasion that was not amenable to reconstructive surgery, six had metastases that had been missed in preoperative imaging and two had benign pathology (chronic pancreatitis). Of the six patients with occult metastases, four patients demonstrated metastases in the liver (three on the liver

surface, one in the posterior gallbladder wall) and two showed metastases in the omentum. The total patient group ( $n = 124$ ) included 30 patients with radiographically unresectable disease secondary to MRI-detected metastases or vascular invasion that was not amenable to reconstructive surgery. Many of these patients underwent a procedure to palliate their symptoms which comprised the placement of plastic biliary stents with or without duodenal stents and was carried out in the gastroenterology laboratory by an experienced endoscopist.

### Determining the costs of operative and non-operative management

Using ICD-9 codes, we found financial records for all patients hospitalized for the management of pancreatic adenocarcinoma between April 2008 and April 2009. These included all of our institution's hepatobiliary surgeons' patients, many of whom did not receive preoperative MRI. A review of these records yielded average costs for patients undergoing pancreaticoduodenectomy, operative bypass and endoscopic palliation; these are summarized in Table 1.

The average costs of endoscopic palliation were further divided into those for patients who received the procedure as outpatients and those for inpatients. We could not determine the proportion of patients receiving outpatient palliation. Therefore, in determining the cost of our practice, we included the cost of inpatient palliation only. In the time under study, 22.3% of patients received duodenal stenting and 33.3% required anaesthesia. The average costs incurred by patients receiving endoscopic palliation were US\$2517.50/patient in the endoscopy suite and US\$11 304.00/patient for an entire inpatient hospitalization. As the amount and type of preoperative imaging were variable, we subtracted the imaging costs. Incidentally, the cost of an MRI pancreas protocol was US\$498.66, whereas that of a CT pancreas protocol was US\$207.39.

The total cost of hospitalization for the average patient receiving a Whipple procedure was US\$26 122.43. The total cost of an operative bypass was US\$21 957.18 and the total cost of palliative stenting was US\$11 304.00. Therefore, the cost of treating all patients in this MRI-driven practice series was US\$2 159 058.73.

### The costs of SL in an MRI-driven practice

The costs of SL are detailed in Table 2. Periprocedure laboratory and pharmacology costs, which are included in the total costs for hospitalized patients, are explicitly added to the costs of outpatient laparoscopy in Table 1. From these data we could then derive the cost of SL with (US\$1538.61) or without (US\$2966.25) laparotomy (Table 1).

We may then apply these costs to our case series. The cost of treating our patients with resectable disease by Whipple procedure is now US\$27 661.04; the cost of treating unresectable disease by palliative double-bypass is now US\$23 495.79, and the cost of treating metastatic disease with SL followed by palliative endos-

**Table 1** Per patient costs of hospitalization for patients treated for pancreatic adenocarcinoma by a Whipple procedure, operative bypass or endoscopic palliation with stents. The cost of laparoscopy is added to each category. The cost of outpatient management of unresectable disease is constructed from an itemized list of costs, presuming no hospitalization after laparoscopy

| Categories of cost         | Whipple procedure, US\$ | Operative bypass, US\$ | Endoscopic palliation with stents, US\$ | Outpatient endoscopic palliation, US\$ |
|----------------------------|-------------------------|------------------------|---|--|
| Hospital floor             | 11 631.63               | 6646.54                | 4679.76                                 | N/A                                    |
| OR or GI laboratory        | 4928.54                 | 5309.02                | 2517.50                                 | 2517.50                                |
| Anaesthesia                | 1148.20                 | 1551.00                | 219.12                                  | 219.12                                 |
| Surgical pathology         | 614.27                  | 385.80                 | See laparoscopy                         | See laparoscopy                        |
| Post-anaesthesia care unit | 618.25                  | 599.63                 | See laparoscopy                         | See laparoscopy                        |
| Blood bank                 | 812.37                  | 756.35                 | 687.79                                  | N/A                                    |
| Chemistry laboratory       | 963.78                  | 700.78                 | 644.46                                  | 111.01                                 |
| Microbiology laboratory    | 206.69                  | 217.70                 | 138.33                                  | N/A                                    |
| Pharmacology               | 3362.72                 | 4153.53                | 2136.07                                 | 129.29                                 |
| Respiratory                | 1212.08                 | 991.02                 | N/A                                     | N/A                                    |
| Rehabilitation             | 623.90                  | 645.81                 | 280.97                                  | N/A                                    |
| <b>Total</b>               | <b>26 122.43</b>        | <b>21 957.18</b>       | <b>11 304.00</b>                        | <b>3415.14</b>                         |
| Add laparoscopy            | 1538.61                 | 1538.61                | 2966.25                                 | 2966.25                                |
| <b>New total</b>           | <b>27 661.04</b>        | <b>23 495.79</b>       | <b>14 270.29</b>                        | <b>5943.17</b>                         |

OR, operating room; GI, gastrointestinal; N/A, not applicable

**Table 2** Costs of staging laparoscopy (SL) constructed from an itemized list of costs derived from financial records at our institution

| Categories of cost             | Costs of SL alone, US\$ | Add to costs of laparotomy? |
|--------------------------------|-------------------------|-----------------------------|
| Post-anaesthesia care          | 400.38                  | No                          |
| Trocars                        | 415.04                  | Yes                         |
| Scissor tip                    | 46.30                   | Yes                         |
| Warmer seals                   | 4.50                    | Yes                         |
| Insufflation tubing            | 7.78                    | Yes                         |
| Bovie pieces                   | 10.91                   | No                          |
| Harmonic scalpel               | 486.59                  | Yes                         |
| Bair hugger                    | 13.77                   | No                          |
| Urine meter                    | 22.49                   | No                          |
| Sterile drape set              | 44.88                   | No                          |
| Suction set                    | 45.57                   | No                          |
| Staplers                       | 14.24                   | No                          |
| Spontaneous compression device | 24.65                   | No                          |
| Bispectral index monitor       | 24.01                   | No                          |
| Intravenous tubing and kit     | 40.68                   | No                          |
| Chlorhexidine                  | 6.06                    | No                          |
| DermaBond 2 pack               | 62.90                   | No                          |
| Operating room time (30 min)   | 396.00                  | Yes                         |
| Anaesthetist (30 min)          | 182.40                  | Yes                         |
| Surgical pathology             | 717.10                  | No                          |
| <b>Total</b>                   | <b>2966.25</b>          | <b>1538.61</b>              |

copy in the inpatient setting is US\$14 270.29. The total cost of this practice is therefore US\$2 236 026.19.

The costs of outpatient endoscopic palliation are further delineated in Table 2. By combining the costs of endoscopy with those of laparoscopy and its periprocedure, we can ascertain the costs of completely outpatient management. The total per patient cost of this strategy is US\$5943.17.

### Cost-effectiveness of SL

Staging laparoscopy changes the treatment strategy by redirecting patients with metastatic disease from the OR to the endoscopy suite. As endoscopic palliation is cheaper than operative management, the more patients who are switched to endoscopy, the cheaper the practice. However, as there is added cost to utilizing SL, its cost-effectiveness depends on its yield of metastases. In our series, 21 patients had unresectable disease at laparotomy and six of these had metastases. The cost of adding SL directly to the MRI-driven practice would increase the cost of inpatient management by US\$76 967.46 (3.6%). If we add the cost of laparoscopy to that of all procedures, using the formula established earlier, the number of metastases found on laparoscopy that would render the procedure cost-effective is 14.30 in inpatient management and 7.54 in outpatient management.

### Discussion

The goal of SL is to spare patients with inoperable disease from laparotomy. Similarly, the cost-effectiveness of SL depends on the proportion of patients redirected from the OR to the endoscopy suite and hopefully spared from hospitalization. This proportion

further depends on the number of metastases *discoverable* at laparotomy and thus the number of metastases missed on preoperative imaging. Beyond these considerations, the value of SL depends on surgeon and patient preference for operative vs. endoscopic palliation. Staging laparoscopy is only useful if endoscopic palliation is preferred over operative bypass in operative candidates. We found that, for SL to be cost-effective, the number of metastases detected at SL had to be greater than the number missed by preoperative MRI, even if metastatic disease was managed entirely on an outpatient basis. Given the paucity of MRI-occult metastases, in this cost-effectiveness analysis of SL in an MRI-driven practice, we find that SL is not a cost-effective procedure.

These results are strengthened by the advantages conferred upon SL by the study's five simplifying assumptions. It was assumed, first, that SL would detect all MRI-occult metastases; second, that SL would have no complications; third, that SL would not lengthen the hospitalization; fourthly, that SL could be undertaken entirely on an outpatient basis. Finally, we made our calculations on the assumption that all patients receiving palliative endoscopy in the non-SL group were inpatients, but that patients in the SL group received palliation as outpatients, adding considerable cost to the MRI-driven practice.

These assumptions were very kind to SL. Prior studies of SL show a 1.7–5.1% rate of minor complications, a 0.7–2.3% rate of major complications (requiring conversion to an open procedure or transfusion) and a 0.49% rate of death.<sup>27,28</sup> Although our methods capture the added hospital costs associated with open procedures (i.e. they represent the average total costs of hospitalization for all patients undergoing operative management), they do not capture those incidental costs that may be associated with SL. Furthermore, although this may reflect either the location of the deposit or operator error, 7–35% of patients receiving SL are found to have metastases that are discovered at laparotomy.<sup>6,9,17,21,22</sup>

For these reasons, SL has become controversial. Some practitioners endorse the practice for all patients with radiographically resectable disease<sup>9,24</sup> and some concede that its role is marginalized by good preoperative imaging.<sup>21,23</sup> Others propose that SL should be applied selectively in those patients with specific clinical features that have been shown retrospectively to predict the presence of occult metastases, such as extreme back pain, weight loss, elevated tumour markers and tumours located in the pancreatic tail.<sup>5,10,25,29</sup> None of these studies, however, have evaluated the utility of SL after a preoperative MRI and no study has addressed whether it is best to redirect patients who are candidates for intra-abdominal surgery from operative to endoscopic bypasses.

Our study has limitations. Firstly, this is a retrospective study and therefore subject to the limitations intrinsic to this sort of inquiry. Secondly, we did not study the clinical presentations of our patients and therefore we cannot comment on the use of a selective approach to SL. Thirdly, these costs are those of our institution alone and therefore limit the generalizability of our

findings. Fourthly, our study represents an indirect evaluation of SL: the added cost of SL is a calculation based on the costs delineated in Table 2. However, the costs presented are generously low. Furthermore, by granting several advantages to SL in this indirect evaluation, including perfect yield, we have presented the upper limit of this practice's cost-effectiveness.

This study of our institution's experience with preoperative MRI in the treatment of pancreatic head lesions does not support the incorporation of routine SL. Further studies are needed to prospectively determine the *cost-effectiveness* of this procedure in both CT- and MRI-driven practices. Additionally, the *value* of SL ought to be determined by investigating the optimal approach to patients with inoperable disease using cost-effectiveness data that take account of data on mortality and quality of life after each procedure.

#### Conflicts of interest

None declared.

#### References

1. Warshaw AL, Fernandez-del Castillo C. (1992) Pancreatic carcinoma. *N Engl J Med* 326:455–465.
2. Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr. (2006) The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. *Ann Oncol* 17:189–199.
3. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. (2008) Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. *JOP* 9:99–132.
4. Bipat S, Phoa SS, van Delden OM, Bossuyt PM, Gouma DJ, Laméris JS *et al.* (2005) Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. *J Comput Assist Tomogr* 29:438–445.
5. Pisters PWT, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. (2001) Laparoscopy in the staging of pancreatic cancer. *Br J Surg* 88:325–337.
6. Vollmer CM, Drebin JA, Middleton WD, Teefey SA, Linehan DC, Soper NJ *et al.* (2002) Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. *Ann Surg* 235:1–7.
7. Nieveen van Dijkum EJ, Romijn MG, Terwee CB, de Wit LT, van der Meulen JH, Lameris HS *et al.* (2003) Laparoscopic staging and subsequent palliation in patients with peripancreatic carcinoma. *Ann Surg* 237:66–73.
8. de Castro SM, Tilleman EH, Busch OR, van Delden OM, Laméris JS, van Gulik TM *et al.* (2004) Diagnostic laparoscopy for primary and secondary liver malignancies: impact of improved imaging and changed criteria for resection. *Ann Surg Oncol* 11:522–529.
9. Enestvedt CK, Mayo SC, Diggs BS, Mori M, Austin DA, Shipley DK *et al.* (2008) Diagnostic laparoscopy for patients with potentially resectable pancreatic adenocarcinoma: is it cost-effective in the current era? *J Gastrointest Surg* 12:1177–1184.
10. Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG. (2009) Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? *J Am Coll Surg* 208:87–95.
11. Velasco JM, Rossi H, Hieken TJ, Fernandez M. (2000) Laparoscopic ultrasound enhances diagnostic laparoscopy in the staging of intra-abdominal neoplasms. *Am Surg* 66:407–411.

12. Megibow AJ, Zhou XH, Rotterdam H, Francis IR, Zerhouni EA, Balfe DM *et al.* (1995) Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability – report of the Radiology Diagnostic Oncology Group. *Radiology* 195:327–332.
13. Hochwald SN, Rofsky NM, Dobryansky M, Shamamian P, Marcus SG. (1999) Magnetic resonance imaging with magnetic resonance cholangiopancreatography accurately predicts resectability of pancreatic carcinoma. *J Gastrointest Surg* 3:506–511.
14. Lopez Hänninen E, Amthauer H, Hosten N, Ricke J, Böhmig M, Langrehr J *et al.* (2002) Prospective evaluation of pancreatic tumours: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. *Radiology* 224:34–41.
15. Tapper EB, Kalb B, Martin D, Kooby D, Adsay NV, Sarmiento JM. (2010) An MRI-driven practice: a new perspective on MRI for the evaluation of adenocarcinoma of the head of the pancreas. *J Gastrointest Surg* 14:1292–1297.
16. Kwon AH, Inui H, Kamiyama Y. (2002) Preoperative laparoscopic examination using surgical manipulation and ultrasonography for pancreatic lesions. *Endoscopy* 34:464–468.
17. Liu RC, Traverso LW. (2005) Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. *Surg Endosc* 19:638–642.
18. Maire F, Sauvanet A, Trivin F, Hammel P, O'Toole D, Palazzo L *et al.* (2004) Staging of pancreatic head adenocarcinoma with spiral CT and endoscopic ultrasonography: an indirect evaluation of the usefulness of laparoscopy. *Pancreatol* 4:436–440.
19. Morganti AG, Brizi MG, Macchia G, Sallustio G, Costamagna G, Alfieri S *et al.* (2005) The prognostic effect of clinical staging in pancreatic adenocarcinoma. *Ann Surg Oncol* 12:145–151.
20. Rumstadt B, Schwab M, Schuster K, Hagmuller E, Trede M. (1997) The role of laparoscopy in the preoperative staging of pancreatic carcinoma. *J Gastrointest Surg* 1:245–250.
21. Friess H, Kleeff J, Silva JC, Sadowski C, Baer HU, Buchler MW. (1998) The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. *J Am Coll Surg* 186:675–682.
22. Tilleman EH, Kuiken BW, Phoa SS, de Castro SM, Busch OR, Obertop H *et al.* (2004) Limitation of diagnostic laparoscopy for patients with a periampullary carcinoma. *Eur J Surg Oncol* 30:658–662.
23. White R, Winston C, Gonen M, D'Angelica M, Jarnagin W, Fong Y *et al.* (2008) Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. *J Am Coll Surg* 206:445–450.
24. Andren-Sandberg A, Lindberg CG, Lundstedt C, Ihse I. (1998) Computed tomography and laparoscopy in the assessment of the patient with pancreatic cancer. *J Am Coll Surg* 186:35–40.
25. Holzman MD, Reintgen KL, Tyler DS, Pappas TN. (1997) The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies. *J Gastrointest Surg* 1:236–243.
26. Obertop H, Gouma DJ. (1999) Essentials in biliopancreatic staging: a decision analysis. *Ann Oncol* 10 (Suppl. 4):150–152.
27. Kane MG, Krejs GJ. (1984) Complications of diagnostic laparoscopy in Dallas: a 7-year prospective study. *Gastrointest Endosc* 30:237–240.
28. Vargas C, Jeffers LJ, Bernstein D, Reddy KR, Munnangi S, Behar S *et al.* (1995) Diagnostic laparoscopy: a 5-year experience in a hepatology training programme. *Am J Gastroenterol* 90:1258–1262.
29. Schlieman MG, Ho HS, Bold RJ. (2003) Utility of tumour markers in determining resectability of pancreatic cancer. *Arch Surg* 138:951–955; discussion 955–956.